Theratechnologies Inc. (TSE:TH - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$1.72 and traded as high as C$1.77. Theratechnologies shares last traded at C$1.73, with a volume of 12,580 shares.
Theratechnologies Stock Down 2.9 %
The company has a current ratio of 1.10, a quick ratio of 0.64 and a debt-to-equity ratio of 562.07. The company has a market cap of C$77.25 million, a price-to-earnings ratio of -9.33, a P/E/G ratio of -8.50 and a beta of 1.73. The business has a fifty day moving average price of C$1.72 and a two-hundred day moving average price of C$1.79.
Theratechnologies (TSE:TH - Get Free Report) last posted its earnings results on Thursday, October 10th. The company reported C$0.09 earnings per share for the quarter. Theratechnologies had a negative return on equity of 1,116.86% and a negative net margin of 8.47%. The firm had revenue of C$30.96 million during the quarter. On average, equities analysts predict that Theratechnologies Inc. will post 0.0298643 earnings per share for the current year.
Theratechnologies Company Profile
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Featured Articles
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.